BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
- Conditions
- HIV Infection
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 249
- Registration Number
- NCT01389310
- Locations
- 🇧🇪
Hospital St Pierre, Brussels, Belgium
🇩🇪German Competence Network, Frankfurt, Germany
🇷🇴Victor Babes Hospital, Bucharest, Romania
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 914
- Registration Number
- NCT01386359
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸Baystate Medical Center, Springfield, Massachusetts, United States
🇺🇸Barnes-Jewish Hospital, Saint Louis, Missouri, United States
Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression
- Conditions
- Depression
- Interventions
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 976
- Registration Number
- NCT01369095
- Locations
- 🇺🇸
Mclean Hospital, Belmont, Massachusetts, United States
🇺🇸Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸Pacific Clinical Research Medical Group, Orange, California, United States
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
- Conditions
- Precursor T-Cell Lymphoblastic LymphomaLymphoblastic Leukemia, Acute T-cell
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 31
- Registration Number
- NCT01363817
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
- Conditions
- Depression
- Interventions
- First Posted Date
- 2011-05-27
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 789
- Registration Number
- NCT01361555
- Locations
- 🇺🇸
Red Oak Psychiatry Associates, Pa, Houston, Texas, United States
🇺🇸California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States
🇺🇸Schuster Medical Research Institute, Sherman Oaks, California, United States
Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 350
- Registration Number
- NCT01359644
- Locations
- 🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸Research And Education, Inc., San Diego, California, United States
🇺🇸University Of Florida Hepatology, Gainesville, Florida, United States
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Biological: Anti-CXCR4 (BMS-936564)Biological: BortezomibBiological: LenalidomideBiological: Dexamethasone
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT01359657
- Locations
- 🇺🇸
University Of Washington School Of Medicine, Seattle, Washington, United States
🇺🇸University Of Kansas Cancer Center And Medical Pavillion, Westwood, Kansas, United States
🇺🇸Dana Faber Cancer Institute, Boston, Massachusetts, United States
Phase I Biomarker Study (BMS-936558)
- Conditions
- Renal Cell Carcinoma
- Interventions
- Drug: BMS-936558 (Anti-PD-1)
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 119
- Registration Number
- NCT01358721
- Locations
- 🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Inst, Boston, Massachusetts, United States
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 70
- Registration Number
- NCT01357655
- Locations
- 🇺🇸
Tennessee Oncology Pllc, Nashville, Tennessee, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
- Conditions
- Juvenile Idiopathic Arthritis
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 800
- Registration Number
- NCT01357668
- Locations
- 🇺🇸
Local Institution - 0060, Little Rock, Arkansas, United States
🇺🇸Local Institution - 0001, Princeton, New Jersey, United States
🇺🇸Local Institution - 0059, Cincinnati, Ohio, United States